Long-term bisphosphonate use may damage jaw.(News)

Prolonged use of bisphosphonate therapy can lead to osteonecrosis of the jaw--a previously unrecognized and potentially serious complication that can often be avoided, according to Salvatore Ruggiero, M.D.

Patients on intravenous therapy face the highest risk regardless of whether they are taking the medication for cancer or for osteoporosis; the risk is lower, although not absent, in those taking oral bisphosphonates, said Dr. Ruggiero, who is chief of oral and maxillofacial surgery at Long Island Jewish Medical Center in New Hyde Park, N.Y.

"The push is to alert physicians that this is a potential problem, so that before they start a patient on bisphosphonates, they send them to a dentist to extract any teeth that are nonrestorable," he told this newspaper. "Prevention and early detection are important for preserving the jawbone in these individuals."

In his experience, the majority of cases have been associated with infections following dental surgeries such as tooth extractions. However, necrosis has also occurred spontaneously in a significant number of patients, he said.

For this reason he recommends all patients on long-term bisphosphonate therapy have two or three preventive dental visits per year, and that physicians be alert for any early signs of necrosis.

Patients should be alert to "things like tooth pain, swelling, numbness of the lip and chin, or pain within the jaw. This is not a very difficult diagnosis to make. You basically have to look in the mouth and if you see exposed bone it is very clear," he said.

Dr. Ruggiero's published research (J. Oral Maxillofac. Surg. 2004;62:527-34) has prompted warnings from the Food and Drug Administration, as well as from Novartis, which manufactures the intravenous bisphosphonates pamidronate disodium (Aredia) ...